Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Safety of low-dose anticoagulation in extracorporeal membrane oxygenation using the Permanent Life Support System: a retrospective observational study

  • Kyungsub Song (Department of Thoracic and Cardiovascular Surgery, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Jae Bum Kim (Department of Thoracic and Cardiovascular Surgery, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine)
  • Received : 2023.04.02
  • Accepted : 2023.05.04
  • Published : 2023.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Bleeding and thrombosis are major complications associated with high mortality in extracorporeal membrane oxygenation (ECMO) management. Anticoagulant therapy should be adequate to reduce thrombosis. However, related studies are limited. Methods: We retrospectively reviewed all patients supported with ECMO at a single institution between January 2014 and July 2022 and included those on all types of ECMO using the Permanent Life Support System. Patients were classified into two groups according to their measured mean activated partial thromboplastin time (aPTT) during ECMO management: a high-anticoagulation (AC) group (aPTT, ≥55 seconds; n=52) and a low-AC group (aPTT, <55 seconds; n=79). The primary outcome was thrombotic or bleeding events during ECMO. Results: We identified 10 patients with bleeding; significantly more of these patients were in the high-AC group (n=8) than in the low-AC group (15.4% vs. 2.5%, p=0.01). However, thrombus events and oxygenator change-free times were not significantly different between the two groups. Four patients in the high-AC group died of bleeding complications (brain hemorrhage, two; hemopericardium, one; and gastrointestinal bleeding, one). One patient in the low-AC group developed a thrombus and died of ECMO dysfunction due to circuit thrombosis. Conclusion: Heparin did not significantly improve thrombotic outcomes. However, maintaining an aPTT of ≥55 seconds was a significant risk factor for bleeding events, especially those associated with mortality.

Keywords

References

  1. McMichael AB, Ryerson LM, Ratano D, Fan E, Faraoni D, Annich GM. 2021 ELSO adult and pediatric anticoagulation guidelines. ASAIO J 2022;68:303-10. https://doi.org/10.1097/MAT.0000000000001652
  2. Sklar MC, Sy E, Lequier L, Fan E, Kanji HD. Anticoagulation practices during venovenous extracorporeal membrane oxygenation for respiratory failure. A systematic review. Ann Am Thorac Soc 2016;13:2242-50. https://doi.org/10.1513/AnnalsATS.201605-364SR
  3. Wood KL, Ayers B, Gosev I, Kumar N, Melvin AL, Barrus B, et al. Venoarterial-extracorporeal membrane oxygenation without routine systemic anticoagulation decreases adverse events. Ann Thorac Surg 2020;109:1458-66. https://doi.org/10.1016/j.athoracsur.2019.08.040
  4. Lv X, Deng M, Wang L, Dong Y, Chen L, Dai X. Low vs standardized dose anticoagulation regimens for extracorporeal membrane oxygenation: a meta-analysis. PLoS One 2021;16:e0249854.
  5. Aubron C, McQuilten Z, Bailey M, Board J, Buhr H, Cartwright B, et al. Low-dose versus therapeutic anticoagulation in patients on extracorporeal membrane oxygenation: a pilot randomized trial. Crit Care Med 2019;47:e563-71. https://doi.org/10.1097/CCM.0000000000003780
  6. Byun JH, Jang IS, Kim JW, Koh EH. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy. Blood Res 2016;51:171-4. https://doi.org/10.5045/br.2016.51.3.171
  7. Sy E, Sklar MC, Lequier L, Fan E, Kanji HD. Anticoagulation practices and the prevalence of major bleeding, thromboembolic events, and mortality in venoarterial extracorporeal membrane oxygenation: a systematic review and meta-analysis. J Crit Care 2017;39:87-96. https://doi.org/10.1016/j.jcrc.2017.02.014
  8. Raiten JM, Wong ZZ, Spelde A, Littlejohn JE, Augoustides JG, Gutsche JT. Anticoagulation and transfusion therapy in patients requiring extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth 2017;31:1051-9. https://doi.org/10.1053/j.jvca.2016.08.011
  9. Annich GM, Zaulan O, Neufeld M, Wagner D, Reynolds MM. Thromboprophylaxis in extracorporeal circuits: current pharmacological strategies and future directions. Am J Cardiovasc Drugs 2017;17:425-39. https://doi.org/10.1007/s40256-017-0229-0
  10. Tomasko J, Prasad SM, Dell DO, DeCamp MM, Bharat A. Therapeutic anticoagulation-free extracorporeal membrane oxygenation as a bridge to lung transplantation. J Heart Lung Transplant 2016;35:947-8. https://doi.org/10.1016/j.healun.2016.04.005
  11. Krueger K, Schmutz A, Zieger B, Kalbhenn J. Venovenous extracorporeal membrane oxygenation with prophylactic subcutaneous anticoagulation only: an observational study in more than 60 patients. Artif Organs 2017;41:186-92. https://doi.org/10.1111/aor.12737
  12. Buscher H, Vukomanovic A, Benzimra M, Okada K, Nair P. Blood and anticoagulation management in extracorporeal membrane oxygenation for surgical and nonsurgical patients: a single-center retrospective review. J Cardiothorac Vasc Anesth 2017;31:869-75. https://doi.org/10.1053/j.jvca.2016.10.015
  13. Pieri M, Agracheva N, Bonaveglio E, Greco T, De Bonis M, Covello RD, et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. J Cardiothorac Vasc Anesth 2013;27:30-4. https://doi.org/10.1053/j.jvca.2012.07.019
  14. Lazzara RR, Magovern JA, Benckart DH, Maher TD Jr, Sakert T, Magovern GJ Jr, et al. Extracorporeal membrane oxygenation for adult post cardiotomy cardiogenic shock using a heparin bonded system. ASAIO J 1993;39:M444-7. https://doi.org/10.1097/00002480-199307000-00058
  15. Lamarche Y, Chow B, Bedard A, Johal N, Kaan A, Humphries KH, et al. Thromboembolic events in patients on extracorporeal membrane oxygenation without anticoagulation. Innovations (Phila) 2010;5:424-9. https://doi.org/10.1177/155698451000500608
  16. Chung YS, Cho DY, Sohn DS, Lee WS, Won H, Lee DH, et al. Is stopping heparin safe in patients on extracorporeal membrane oxygenation treatment? ASAIO J 2017;63:32-6. https://doi.org/10.1097/MAT.0000000000000442
  17. Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, et al. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc 2013;15:172-8. https://doi.org/10.1016/S1441-2772(23)01792-1
  18. Lequier L, Horton SB, McMullan DM, Bartlett RH. Extracorporeal membrane oxygenation circuitry. Pediatr Crit Care Med 2013;14(5 Suppl 1):S7-12. https://doi.org/10.1097/PCC.0b013e318292dd10
  19. Yeo HJ, Kim DH, Jeon D, Kim YS, Cho WH. Low-dose heparin during extracorporeal membrane oxygenation treatment in adults. Intensive Care Med 2015;41:2020-1. https://doi.org/10.1007/s00134-015-4015-7